This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abizaid, A. Articles by Sousa, J. E. Search for Related Content PubMed PubMed Citation Articles by Abizaid, A. Articles by Sousa, J. E.

First human experience with the 17-beta-estradiol–eluting stent

The estrogen and stents to eliminate restenosis (EASTER) trial

Alexandre Abizaid, MD, PhD^*,*, Mariano Albertal, MD, PhD^*, Marco A. Costa, MD, PhD, Andrea S. Abizaid, MD, PhD^*, Rodolfo Staico, MD^*, Fausto Feres, MD, PhD^*, Luiz A. Mattos, MD, PhD^*, Amanda G. M. R. Sousa, MD, PhD^*, Jeffrey Moses, MD, Nicholas Kipshidize, MD, Gary S. Roubin, MD, Roxana Mehran, MD, Gishel New, MD^||, Martin B. Leon, MD and J. Eduardo Sousa, MD, PhD^*

^* Institute Dante Pazzanese of Cardiology, São Paulo, Brazil
University of Florida-Shands, Jacksonville, Florida, USA
Lenox Hill Hospital, New York, New York, USA
Cardiovascular Research Foundation, New York, New York, USA
^|| Box Hill Hospital, Melbourne, Australia

View larger version (13K): [in a new window]   Figure 1 Cumulative distribution curves of in-stent (A) and in-lesion (B) percentage diameter stenosis (%DS) and in-stent late loss (C) at six-month angiographic follow-up.

View larger version (16K): [in a new window]   Figure 2 Late-loss comparison between phosphorylcholine (PC)-coated stent trials with and without estradiol.

View larger version (9K): [in a new window]   Figure 3 Graph showing the phosphorylcholine polymer local delivery pharmacokinetics of 17-beta-estradiol. Total drug delivery is completed within the first 24 h.